Leerink Partners reiterated coverage on ARS Pharmaceuticals with a new price target
$SPRY
Biotechnology: Pharmaceutical Preparations
Health Care
Leerink Partners reiterated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $20.00 from $19.00 previously